CTLA4 and hypophysitis: As the incidence of ICI-induced hypophysitis is higher with anti-CTLA4-mAbs than anti-PD1/PD1L mAbs most data on the pathogenesis of ICI-induced pituitary damage derive from studies on anti-CTLA4-mAbs (3, 30).